CN101601616B - 一种颅内西罗莫司药物释放血管支架及其制备方法 - Google Patents
一种颅内西罗莫司药物释放血管支架及其制备方法 Download PDFInfo
- Publication number
- CN101601616B CN101601616B CN 200910088181 CN200910088181A CN101601616B CN 101601616 B CN101601616 B CN 101601616B CN 200910088181 CN200910088181 CN 200910088181 CN 200910088181 A CN200910088181 A CN 200910088181A CN 101601616 B CN101601616 B CN 101601616B
- Authority
- CN
- China
- Prior art keywords
- sirolimus
- medicament
- intravascular stent
- support bar
- intracranial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 323
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims abstract description 294
- 229960002930 sirolimus Drugs 0.000 title claims abstract description 294
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims abstract description 294
- 238000007917 intracranial administration Methods 0.000 title claims abstract description 68
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 238000000576 coating method Methods 0.000 claims abstract description 139
- 239000011248 coating agent Substances 0.000 claims abstract description 109
- 238000005507 spraying Methods 0.000 claims abstract description 31
- 238000010147 laser engraving Methods 0.000 claims abstract description 15
- 238000005498 polishing Methods 0.000 claims abstract description 15
- 238000001035 drying Methods 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims description 113
- 229940079593 drug Drugs 0.000 claims description 78
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 44
- 210000003205 muscle Anatomy 0.000 claims description 30
- 238000001291 vacuum drying Methods 0.000 claims description 20
- 229920006237 degradable polymer Polymers 0.000 claims description 19
- 230000001413 cellular effect Effects 0.000 claims description 18
- 238000010276 construction Methods 0.000 claims description 18
- 238000005520 cutting process Methods 0.000 claims description 13
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 claims description 12
- 239000002131 composite material Substances 0.000 claims description 11
- 238000011068 loading method Methods 0.000 claims description 11
- 238000004140 cleaning Methods 0.000 claims description 10
- 238000007711 solidification Methods 0.000 claims description 10
- 230000008023 solidification Effects 0.000 claims description 10
- 230000001360 synchronised effect Effects 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 abstract description 9
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract description 7
- 230000005012 migration Effects 0.000 abstract description 4
- 238000013508 migration Methods 0.000 abstract description 4
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical class [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 abstract 2
- 238000003698 laser cutting Methods 0.000 abstract 2
- 230000008692 neointimal formation Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 72
- 239000004626 polylactic acid Substances 0.000 description 72
- 239000002904 solvent Substances 0.000 description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 210000004351 coronary vessel Anatomy 0.000 description 11
- 210000001367 artery Anatomy 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 208000007536 Thrombosis Diseases 0.000 description 9
- 238000013461 design Methods 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 6
- 150000001335 aliphatic alkanes Chemical class 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 150000007984 tetrahydrofuranes Chemical class 0.000 description 6
- 238000009826 distribution Methods 0.000 description 5
- 210000003038 endothelium Anatomy 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012890 simulated body fluid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910088181 CN101601616B (zh) | 2009-07-10 | 2009-07-10 | 一种颅内西罗莫司药物释放血管支架及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910088181 CN101601616B (zh) | 2009-07-10 | 2009-07-10 | 一种颅内西罗莫司药物释放血管支架及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101601616A CN101601616A (zh) | 2009-12-16 |
CN101601616B true CN101601616B (zh) | 2011-09-14 |
Family
ID=41467614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200910088181 Expired - Fee Related CN101601616B (zh) | 2009-07-10 | 2009-07-10 | 一种颅内西罗莫司药物释放血管支架及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101601616B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101745153B (zh) * | 2010-01-21 | 2014-08-20 | 万瑞飞鸿(北京)医疗器材有限公司 | 具有全生物降解药物涂层的钴铬合金动脉支架、支架系统及其制备方法 |
EP3463205B1 (en) * | 2016-05-25 | 2024-07-03 | Q3 Medical Devices Limited | Biodegradable supporting device |
JP2021512730A (ja) * | 2018-02-23 | 2021-05-20 | エフェモラル メディカル インコーポレイテッド | 静脈閉塞性疾患の治療のための吸収性血管内デバイス |
CN110811735A (zh) * | 2019-11-21 | 2020-02-21 | 中国科学院金属研究所 | 一种局部增强型镍钛合金颅内支架 |
CN112741720A (zh) * | 2021-01-21 | 2021-05-04 | 北京久事神康医疗科技有限公司 | 一种可回收颅内药物洗脱支架系统 |
CN116099058A (zh) * | 2022-10-26 | 2023-05-12 | 北京美中双和医疗器械股份有限公司 | 一种药物涂层及其制备方法 |
-
2009
- 2009-07-10 CN CN 200910088181 patent/CN101601616B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101601616A (zh) | 2009-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101601616B (zh) | 一种颅内西罗莫司药物释放血管支架及其制备方法 | |
CN101745153B (zh) | 具有全生物降解药物涂层的钴铬合金动脉支架、支架系统及其制备方法 | |
CN101450229B (zh) | 基质、细胞移植物以及制备和使用它们的方法 | |
US20090112310A1 (en) | Nanoporous Drug Release Structure for Drug Elute Instruments and the Preparation Method Thereof | |
Cardinal et al. | Tissue-engineered vascular grafts as in vitro blood vessel mimics for the evaluation of endothelialization of intravascular devices | |
CN105457105B (zh) | 一种可显影镁合金血管支架 | |
CN101703812B (zh) | 一种聚酰胺66覆膜镍钛合金血管支架及其制备方法 | |
CN106344210A (zh) | 涂药覆膜支架 | |
CN101249287B (zh) | 一种治疗冠心病的血管支架 | |
CN108498208B (zh) | 适用于动脉血管的血管支架 | |
CN101790391A (zh) | 药物洗脱医学装置和方法 | |
CN201551421U (zh) | 一种血管支架 | |
CN100577221C (zh) | 血管支架的表面改性涂层及其制备方法 | |
CN101485902B (zh) | 一种生物可降解雷帕霉素-普罗布考复合药物涂层金属支架 | |
CN101601617B (zh) | 一种颅内紫杉醇药物释放支架及其制备方法 | |
CN113244462B (zh) | 一种防止支架内再狭窄的药物涂层血管支架及制备方法 | |
CN108261559A (zh) | 可吸收铁基器械 | |
CN101502696A (zh) | 一种携载基因和/或药物的医疗器械及其制备方法 | |
CN103212117B (zh) | 具有全生物降解药物涂层的钴铬合金动脉支架系统 | |
CN103990186B (zh) | 一种具有防治再狭窄药物涂层的支架及其制备方法 | |
CN102309781A (zh) | 一种含重组hCREG糖蛋白的冠脉支架及其制备方法 | |
CN104783923A (zh) | 一种层层自组装的小口径组织工程血管及其构建方法 | |
CN206777427U (zh) | 一种植入式完全生物可吸收血管聚合物支架 | |
CN104707185A (zh) | 一种银杏内酯b复合药物洗脱支架 | |
CN109134838B (zh) | 一种硝酸酯可降解生物活性材料及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Intracranial sirolimus medicament-release blood vessel stent and preparation method thereof Effective date of registration: 20160310 Granted publication date: 20110914 Pledgee: Beijing technology intellectual property financing Company limited by guarantee Pledgor: Medfavour (Beijing) Medical Equipment Co., Ltd. Registration number: 2016990000194 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20170711 Granted publication date: 20110914 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190509 Granted publication date: 20110914 Pledgee: Beijing technology intellectual property financing Company limited by guarantee Pledgor: Medfavour (Beijing) Medical Equipment Co., Ltd. Registration number: 2016990000194 |
|
PD01 | Discharge of preservation of patent | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20200711 Granted publication date: 20110914 |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110914 Termination date: 20190710 |